The Filing Desk

Arcus Biosciences vs Regenxbio

Arcus Biosciences RCUS · Regenxbio RGNX · Biotechnology

Arcus Biosciences reported revenue of $247 million in fiscal 2025, 1.4 times Regenxbio's $170 million in fiscal 2025. Arcus Biosciences' revenue fell 4.3% in its latest year, and Regenxbio's grew 104.5%. Arcus Biosciences had an operating margin of -156.3%, against -94.6% at Regenxbio. Free cash flow was −$484 million at Arcus Biosciences and −$126 million at Regenxbio.

Side by side

Arcus BiosciencesRegenxbio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$247M$170M
Revenue growth−4.3%104.5%
Revenue growth a year, last 5 years25.9%2.0%
Gross margin——
Operating margin−156.3%−94.6%
Net margin−142.9%−113.8%
Free cash flow−$484M−$126M
Free cash flow margin−195.9%−74.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count19.2%4.2%
Last close$17.43$7.64
P/E at the last close——
Insider trades, last 12 monthssold $10.0 million—
Piotroski F-score0 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arcus BiosciencesRegenxbio
Operating margin
Percent of revenue
Arcus BiosciencesRegenxbio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arcus BiosciencesRegenxbio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arcus Biosciences and Regenxbio pages.